1. Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients' and physicians'perspectives: results from the UC. NORMAL survey. Inflamm Bowel Dis 2009;15:581-588.PMID:
19067414.
2. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910.PMID:
8984031.
3. Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev 2008;28:201-218.PMID:
17464967.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.PMID:
16339095.
5. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13:2328-2332.PMID:
17511032.
6. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-787.PMID:
21209123.
7. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-265.e3.PMID:
22062358.
9. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-972.PMID:
18652603.
10. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-1307.PMID:
19408340.
11. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009;24:1252-1257.PMID:
19220669.
12. García-Bosch O, Gisbert JP, Cañas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717-722.PMID:
23142005.
13. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010;32:522-528.PMID:
20500733.
14. Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011;33:340-348.PMID:
21133961.
15. Armuzzi A, Biancone L, Daperno M, et al. P230 Adalimumab in active ulcerative colitis: a “real-life” observational study. J Crohns Colitis 2012;6(Suppl 1): S101-S101.
16. Ferrante M, Karmiris K, Compernolle G, Ballet V, Vermeire S, Noman M. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. Gut 2011;60(Suppl 3): A72.
18. Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 2015;9(Suppl 1): 35-44.PMID:
26395533.
19. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015;30:1705-1712.PMID:
25974251.
20. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015;60:951-956.PMID:
25326115.
21. Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 2016;10:133-140.PMID:
26661272.
22. Farkas K, Rutka M, Bálint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis: experiences from a single center. Expert Opin Biol Ther 2015;15:1257-1262.PMID:
26134250.
23. Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res 2016;14:15-20.PMID:
26884730.
25. Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016;19:1157-1168.PMID:
26176644.
26. Sood A, Midha V, Sood N, et al. Cyclosporine in the treatment of severe steroid refractory ulcerative colitis: a retrospective analy-sis of 24 cases. Indian J Gastroenterol 2008;27:232-235.PMID:
19405256.
27. Sood A, Midha V, Sharma S, et al. Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience. Indian J Gastroenterol 2014;33:31-34.PMID:
23999683.